BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.
Although targeted therapies are used increasingly in hematologic malignancies, we are unaware of any prior studies of radioimmunotherapy (RAIT) in B-acute lymphoblastic leukemia (ALL), even though this radiosensitive tumor expresses CD22, potentially a good target for this approach. Here, we report a patient with Philadelphia chromosome-positive B-ALL in third relapse who received RAIT with (90) yttrium ((90) Y)-labeled anti-CD22 epratuzumab tetraxetan. Seven weeks after initiating therapy, the patient achieved a BCR-ABL1 molecular remission documented by RT-qPCR, which is now continuing at 6 months while awaiting an allogeneic hematopoietic stem cell transplant. (90) Y-Epratuzumab tetraxetan may be a promising therapeutic option for CD22(+) B-ALL patients.
Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Centre d'Investigation Clinique en Cancérologie (CI2C), Université de Nantes and INSERM CRNCA UMR 892, Nantes, France.
Patrice
P
Chevallier
Caroline
C
Bodet-Milin
Nelly
N
Robillard
Thomas
T
Eugene
Audrey
A
Menard
Claire
C
Le Houerou
Thierry
T
Guillaume
Jacques
J
Delaunay
Martine
M
Escoffre-Barbe
William A
WA
Wegener
David M
DM
Goldenberg
Francoise
F
Kraeber-Bodéré
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D016130:Immunophenotyping; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis; D010641:Phenotype; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D012074:Remission Induction; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000378:metabolism; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D061067:Antibodies, Monoclonal, Humanized; D051918:Sialic Acid Binding Ig-like Lectin 2; D015021:Yttrium Radioisotopes; C448700:epratuzumab; D016044:Fusion Proteins, bcr-abl
B-acute lymphoblastic leukemia; BCR-ABL1; CD22; epratuzumab; radioimmunotherapy; relapse; yttrium